Armon Sharei

Company: SQZ Biotechnologies

Job title: CEO & Founder

Seminars:

2nd Generation Antigen Presenting Cells for Multiple KRAS Mutations 9:30 am

SQZ APC mechanism overcomes challenges of previous cancer vaccines with CD8 T-cell activation and can be enhanced with mRNA cargo combinations SQZ APC clinical program overview: Safety and manufacturability of SQZ’s APC candidate in solid tumors Preclinical data for SQZ’s enhanced APC platform in targeting KRAS G12D and G12V mutationRead more

day: Day Two